Comparing of Pulmatrix Inc. (PULM) and Sutro Biopharma Inc. (NASDAQ:STRO)

Pulmatrix Inc. (NASDAQ:PULM) and Sutro Biopharma Inc. (NASDAQ:STRO), both competing one another are Biotechnology companies. We will compare their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulmatrix Inc. N/A 85.29 20.56M -6.88 0.00
Sutro Biopharma Inc. 38.42M 6.56 35.32M -2.21 0.00

In table 1 we can see Pulmatrix Inc. and Sutro Biopharma Inc.’s top-line revenue, earnings per share and valuation.


Table 2 has Pulmatrix Inc. and Sutro Biopharma Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Pulmatrix Inc. 0.00% -176.2% -124.7%
Sutro Biopharma Inc. -91.93% 0% 0%


The Current Ratio and Quick Ratio of Pulmatrix Inc. are 1.3 and 1.3 respectively. Its competitor Sutro Biopharma Inc.’s Current Ratio is 3.5 and its Quick Ratio is 3.5. Sutro Biopharma Inc. can pay off short and long-term obligations better than Pulmatrix Inc.

Insider & Institutional Ownership

The shares of both Pulmatrix Inc. and Sutro Biopharma Inc. are owned by institutional investors at 12.7% and 75.3% respectively. Insiders held roughly 7.53% of Pulmatrix Inc.’s shares. Insiders Comparatively, held 8.5% of Sutro Biopharma Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Pulmatrix Inc. 17.55% -8.59% -68.97% -71.95% -91.7% -51.27%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year Pulmatrix Inc. has -51.27% weaker performance while Sutro Biopharma Inc. has 0.33% stronger performance.


On 6 of the 9 factors Sutro Biopharma Inc. beats Pulmatrix Inc.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The companyÂ’s proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis (IPF). It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease. The company has an alliance with Celdara to develop an inhaled biologic to treat IPF. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.